E-viri
PDF
Odprti dostop
-
Corbacioglu, Selim, MD; Carreras, Enric, MD, PhD; Mohty, Mohamad, MD, PhD; Pagliuca, Antonio, MBBS; Boelens, Jaap Jan, MD, PhD; Damaj, Gandhi, MD; Iacobelli, Massimo, MD; Niederwieser, Dietger, MD; Olavarría, Eduardo, MD, PhD; Suarez, Felipe, MD, PhD; Ruutu, Tapani, MD, PhD; Verdonck, Leo, MD, PhD; Hume, Robin, MS; Nejadnik, Bijan, MD; Lai, Chinglin; Finetto, Giorgia; Richardson, Paul, MD
Biology of blood and marrow transplantation, 10/2016, Letnik: 22, Številka: 10Journal Article
Highlights 3 to 5 bullet points with a maximum of 85 characters each including spaces • Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) can be severe • Severe VOD/SOS can develop unpredictably and can be fatal. • Defibrotide has demonstrated efficacy and safety in treatment of VOD/SOS. • Safety and efficacy were consistent with prior studies of defibrotide in VOD/SOS. • Subgroup results lend support to the 25 mg/kg/day recommended dose for defibrotide.
